Current portfolio


Leading Global Clinical Research Organization that supports pharma and biotech companies in managing clinical trials

Parexel offers a comprehensive suite of services across the drug development continuum from outsourced clinical research services to regulatory, market access, and strategy consulting services

  • Sector
  • Country
    United States
  • Responsible Advisor
    Eric Liu
  • Fund
    EQT IX
  • Entry

Private Capital



Parexel offers significant expertise across the drug development continuum and offers a comprehensive suite of outsourced clinical research services, as well as regulatory, market access, and strategy consulting services. Parexel has a strong market position in oncology, biotech, phase II-III trials, and Asia. Over the last few years, Parexel has been a driving force in the market shift towards decentralized clinical trials and increased patient diversity.

Parexel was founded in 1982 and is headquartered in Durham, North Carolina. The company has more than 21,000 employees globally.

Market Trends and Drivers

The Clinical Research market is an attractive industry that is benefitting from secular growth in pharmaceutical R&D spend, increasing clinical trial complexity, growth in biotech funding, and increased outsourcing of clinical research

Investment Potential

EQT and Goldman Sachs Asset Management will support Parexel through accelerating investments into Biotech and Asia, integrating solutions from best-of-breed technology solutions, investing in data & analytics capabilities, and continuing to drive organizational efficiencies to drive best-in-class operational performance

Board of directors

  • Chairperson
    Sheri McCoy
  • Board member
    Susan Salka
  • Board member
    Bill Chase
  • Board member
    Maykin Ho
  • Board member
    Jamie Macdonald
  • Board member
    Michael Bruun
  • Board member
    John Groetelaars
  • Board member
    Peyton Howell


  • CEO
    Peyton Howell
  • CFO
    Greg Rush
EQT logo